Chinese Communist Researcher Stole U.S. Monoclonal Antibody ‘Secrets’… In 2015

( )- We’ve reported many times already about the Chinese Communist Party’s plot to steal American trade secrets and scientific innovation, and today we have more for you. A third scientist employed by GlaxoSmithKline, a global healthcare company that manufactures vaccines and medicines, has pleaded guilty to stealing American trade secrets.

Among those secrets? The science behind several COVID-19 treatments.

Lucy Xi and three other defendants pled guilty to stealing information from GlaxoSmithKline after setting up Renopharma, a Chinese pharmaceutical firm that was backed by the Chinese Communist Party. The scientists positioned their research operation as focusing on developing and researching new anti-cancer drugs.

Xi and her colleagues worked at the GSK base in Upper Merion, Pennsylvania, and stole trade secrets from the company during their time there. Court documents and a statement from the Department of Justice reveal how in 2015, Xi sent Yan Mei a document from GSK that included trade secret data and confidential information.

According to the Justice Department’s notes, an email sent by Xi to her colleague “provided a summary of GSK research into monoclonal antibodies at that time.”

In the body of the email, not the attached file, Xi told her colleague:

“You need to understand it very well. It will help you in your future business.”

Well, that’s not obvious…

Jacqueline Maguire, the FBI Special Agent who runs the Philadelphia Division of the Bureau, said that pharmaceutical companies like GSK invest huge sums of money and time into developing new drugs, ensuring they were safe, and then bringing them to market – so when people steal those trade secrets, it’s a threat to the company and beyond.

“After all, innovation like this propels the U.S. economy,” Maguire added, and reiterated the FBI’s commitment to “enforcing laws that protect the nation’s businesses from such theft.”

Just another example of China stealing American intellectual property and trade secrets…what is President Joe Biden going to do about it?